HLX KRAS Mutation Analysis Case HLX KRAS Tracking
Synonyms |
KRAS |
Allscripts (AEHR) Order Name |
KRAS Mutation Analysis |
Sunrise Clinical Manager (SCM) Order Name |
Not Orderable |
EPIC Order Name |
|
Clinical Info |
ASSAY DESCRIPTION: Kras mutations are detected in different cancers and can predict the response to EGFR inhibitors and guide patient treatment. |
Specimen Type |
Tissue |
Specimen Volume |
4x5 μm unstained FFPE |
Container |
FFPE Slides |
Collection Instructions |
Specimen: 4 unstained 5um FFPE slides (each with an area 50-600 mm(2) are required. If the tumor content is less that 50 % please submit and additional H&E slide for macrodissection. |
Transport Instructions |
|
Specimen Stability |
Room Temperature |
Methodology |
Qualitative Real-Time PCR performed on the Idylla(TM) platform |
Days Performed |
Monday - Friday |
Performing Laboratory |
|
CPT |
81275,81276,88381 |
PDM |
238468 |
Result InterpretationNegative for KRAS Mutation Limitations This assay is qualitative and is not intended to detect minimal residual disease. While covering codons 59 and 117, the assay does not distinguish between mutations occurring on the same nucleotide, i.e., A59E/G/T and A146P/T/V respectively.This assay is designed to detect Q61L (c.182A>T) mutation. Other rare or complex Q61L mutations might not be detected, except for Q61L 182_183AA>TT which is interpreted by the assay as a Q61H mutation. Mutations present below the limit of detection of the assay (5%) might not be detected |
|
Forms |
|
